Pertuzumab (Perjeta)
Immunotherapy · Approved since 2012
Description
Pertuzumab is a humanized monoclonal antibody that targets HER2-positive colorectal cancers, used in combination with trastuzumab for patients whose tumors overexpress or amplify the HER2 protein. In colorectal cancer, pertuzumab is primarily utilized for HER2-positive metastatic disease, which occurs in approximately 2-3% of colorectal cancer patients. This targeted therapy represents a precision medicine approach for a specific molecular subset of colorectal cancer patients who have limited treatment options.
Mechanism of Action
Pertuzumab binds to the extracellular dimerization domain of the HER2 receptor, preventing heterodimerization with other HER family receptors including HER1, HER3, and HER4. By blocking HER2 receptor dimerization, pertuzumab inhibits downstream signaling pathways that promote tumor cell proliferation and survival. When combined with trastuzumab, pertuzumab provides complementary HER2 blockade, as trastuzumab binds to a different epitope on the HER2 receptor.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Perjeta |
| Category | Immunotherapy |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | IV |
| Year Approved | 2012 |
| Clinical Trials | 9 |
Regimens with this Drug
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.